Do we need new treatments for type 2 diabetes?
Diagnosis of type 2 diabetes mellitus encompasses multiple pathophysiological and clinical situations. Type 2 diabetes mellitus is characterized by a long and changing natural history. Personal circumstances and preferences also condition the actual effectiveness and safety of drugs used. In recent decades, modern drugs have markedly expanded and improved therapeutic options. However, their effectiveness remains limited in clinical practice. The main objective of decreasing macrovascular complications is not fully proven. Adverse events, especially hypoglycemia and weight gain, are still frequent and decrease treatment adherence. The constant loss of endogenous islet cell reserve is the main determinant of the need for intensified therapies. Current treatments have failed to improve long-term beta cell mass/function. It is desirable to move forward to obtain new drugs that offer solutions sustainable in the long term. These drugs should be able to fit the individual circumstances and preferences of patients with diabetes mellitus.
Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, España. Electronic address: fgomezperalta@gmail.com.
Fernando
F
Gomez-Peralta
Unidad de Endocrinología y Nutrición, Hospital General de Segovia, Segovia, España.
Cristina
C
Abreu Padín
D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control; D015897:Comorbidity; D048909:Diabetes Complications / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006040:Goals; D006301:Health Services Needs and Demand; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use; D007249:Inflammation; D007328:Insulin / Q000627:therapeutic use; D008017:Life Expectancy; D008055:Lipids / Q000097:blood; D024821:Metabolic Syndrome / Q000097:blood / Q000628:therapy; D050177:Overweight / Q000453:epidemiology; D018384:Oxidative Stress; D057285:Precision Medicine; D012307:Risk Factors; D035703:Therapies, Investigational; D019851:Thrombophilia / Q000188:drug therapy / Q000209:etiology
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008055:Lipids
Antidiabetic drugs; Diabetes; Future treatment; Futuros tratamientos; Fármacos antidiabéticos; Hipoglucemia; Hypoglycemia; Peso; Weight